AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9106321 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 78
Study 8477136 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA (Patient-Controlled Analgesia)
Number of subjects: 54
Study 8477136 — intervention group
Group type: COMPARATOR
Intervention: PCA + CI (Patient-Controlled Analgesia plus Continuous Infusion)
Number of subjects: 54
Study 8477136 — intervention group
Group type: EXPERIMENTAL
Intervention: NCA (Nurse-Controlled Analgesia)
Number of subjects: 54
Study 3942848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 3942848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29847157 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (QUET)
Number of subjects: 33
Study 29847157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 33
Study 27544742 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) achieved group (548 patients, 18.2%)
Number of subjects: 3004
Study 27544742 — intervention group
Group type: COMPARATOR
Intervention: Non-Optimal Medical Therapy (non-OMT) group (2,456 patients)
Number of subjects: 3004
Study 27544742 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) achieved group
Number of subjects: 3004
Study 27544742 — intervention group
Group type: COMPARATOR
Intervention: Non-Optimal Medical Therapy (non-OMT) group
Number of subjects: 3004
Study 24362587 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO and intranasal mometasone furoate (10 μl/day)
Number of subjects: 40
Study 24362587 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO and diclofenac sodium (10 mg/kg/day ip)
Number of subjects: 40
Study 24362587 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO group
Number of subjects: 40
Study 24362587 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to HBO)
Number of subjects: 40
Study 22675945 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo glue
Number of subjects: 0
Study 22675945 — intervention group
Group type: COMPARATOR
Intervention: No Embryo glue (Control)
Number of subjects: 0
Study 20926533 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 257
Study 20926533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 18592627 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed formula
Number of subjects: 175
Study 18592627 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 175
Study 18592627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution
Number of subjects: 175
Study 18592627 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal tea
Number of subjects: 175
Study 18592627 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study 15816571 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation (Group 1)
Number of subjects: 60
Study 15816571 — intervention group
Group type: COMPARATOR
Intervention: Recumbent position (Group 2)
Number of subjects: 60
Study 12553444 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthyretin and albumin markers
Number of subjects: 0
Study 9428876 — intervention group
Group type: EXPERIMENTAL
Intervention: sufentanil/propofol (Group 1)
Number of subjects: 40
Study 9428876 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil/propofol (Group 2)
Number of subjects: 40
Study 7697841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 0.5 mg/kg per hour for 12 hours followed by 0.1 mg/kg per hour
Number of subjects: 68
Study 7697841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 1.0 mg/kg per hour for 12 hours followed by placebo
Number of subjects: 68
Study 7697841 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000 U bolus followed by 1000 U/h titrated to an aPTT 2 to 2.5 times control after 12 hours
Number of subjects: 68
Study 3261140 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 80
Study 3261140 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80
Study 3261140 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 80
Study 3261140 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 80
Study 30510523 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 128
Study 30510523 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Activation (BA)
Number of subjects: 128
Study 28842953 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel body shape descriptors based on 3D body images
Number of subjects: 121
Study 28842953 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models for VAT and SAT
Number of subjects: 121
Study 25778833 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (30 min of moderate-intensity walking)
Number of subjects: 28
Study 25778833 — intervention group
Group type: COMPARATOR
Intervention: Resting (no exercise)
Number of subjects: 28
Study 25778833 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 28
Study 25778833 — intervention group
Group type: COMPARATOR
Intervention: Resting
Number of subjects: 28
Study 25778833 — intervention group
Group type: EXPERIMENTAL
Intervention: EIdiff (difference in EI between exercise and resting)
Number of subjects: 28
Study 25778833 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of 'compensators'/'non-compensators'
Number of subjects: 28
Study 23865624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention consisting of two individually delivered counseling sessions focusing on diet, physical activity, and weight monitoring.
Number of subjects: 250
Study 23865624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 250
Study 23865624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention.
Number of subjects: 250
Study 21663949 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg plus Ezetimibe 10 mg daily
Number of subjects: 9270
Study 21663949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9270
Study 19216002 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing surgical face masks
Number of subjects: 32
Study 19216002 — intervention group
Group type: COMPARATOR
Intervention: No face masks (control group)
Number of subjects: 32
Study 16914464 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate-Lipuro
Number of subjects: 80
Study 16914464 — intervention group
Group type: COMPARATOR
Intervention: Propofol with added lidocaine
Number of subjects: 80
Study 15598773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.16% all-trans retinoic acid (atRA) for 4 days
Number of subjects: 175
Study 15598773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.28% all-trans retinoic acid (atRA) for 4 days
Number of subjects: 175
Study 15598773 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.36% all-trans retinoic acid (atRA) for 4 days
Number of subjects: 175
Study 15598773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 15598773 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN II at baseline
Number of subjects: 175
Study 11719733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine with red wine (12 oz of Blackstone Merlot, 1996)
Number of subjects: 12
Study 11719733 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine with water (control)
Number of subjects: 12
Study 9140320 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given immediately after verapamil 80 mg (conventional formulation)
Number of subjects: 17
Study 9140320 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given 2 hours after verapamil 80 mg (conventional formulation)
Number of subjects: 17
Study 9140320 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given immediately after verapamil 240 mg (slow-release formulation)
Number of subjects: 17
Study 9140320 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given 2 hours after verapamil 240 mg (slow-release formulation)
Number of subjects: 17
Study 9140320 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) given 4 hours after verapamil 240 mg (slow-release formulation)
Number of subjects: 17
Study 7951964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronation orthosis
Number of subjects: 23
Study 7951964 — intervention group
Group type: EXPERIMENTAL
Intervention: Supination orthosis
Number of subjects: 23
Study 7951964 — intervention group
Group type: COMPARATOR
Intervention: Control (no orthosis)
Number of subjects: 23
Study 3904433 — intervention group
Group type: EXPERIMENTAL
Intervention: isoxicam (200 to 400 mg per day, then reduced to 200 mg per day)
Number of subjects: 745
Study 3904433 — intervention group
Group type: COMPARATOR
Intervention: isoxicam (open-label after double-blind phase)
Number of subjects: 745
Study 3904433 — intervention group
Group type: EXPERIMENTAL
Intervention: isoxicam
Number of subjects: 745
Study 27924679 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D supplementation
Number of subjects: 62
Study 27924679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 26744983 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 296
Study 26744983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 23861093 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent alliance with therapist in Family-Based Treatment (FBT)
Number of subjects: 0
Study 23861093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parent alliance in FBT
Number of subjects: 0
Study 23861093 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in alliance scores between mothers and fathers, and parents and their child
Number of subjects: 0
Study 22480146 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant insulin therapy
Number of subjects: 280
Study 22480146 — intervention group
Group type: COMPARATOR
Intervention: Dietary regime
Number of subjects: 280
Study 20450373 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing dentifrice (CT)
Number of subjects: 39
Study 20450373 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 39
Study 18024525 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HSP27 plasma concentration
Number of subjects: 510
Study 18024525 — intervention group
Group type: COMPARATOR
Intervention: Control group (women matched for age and smoking, free of cardiovascular disease)
Number of subjects: 510
Study 17313718 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 3 x 4 g/d for 6 months
Number of subjects: 118
Study 17313718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 15496045 — intervention group
Group type: EXPERIMENTAL
Intervention: ICaps AREDS Formula (Alcon)
Number of subjects: 50
Study 15496045 — intervention group
Group type: COMPARATOR
Intervention: Ocuvite PreserVision (Bausch & Lomb)
Number of subjects: 50
Study 11533794 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (25mg/kg wt)
Number of subjects: 60
Study 11533794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (0.13 mg/kg body wt) with Chloroquine
Number of subjects: 60
Study 11533794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen with Fansidar (33.3mg/kg body wt)
Number of subjects: 60
Study 11533794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen with both Chloroquine and Fansidar
Number of subjects: 60
Study 11533794 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine with Ketotifen
Number of subjects: 60
Study 11533794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen plus Fansidar
Number of subjects: 60
Study 11533794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Chloroquine, Ketotifen, and Fansidar
Number of subjects: 60
Study 9107182 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg BID)
Number of subjects: 32
Study 9107182 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus aspirin (325 mg/d)
Number of subjects: 32
Study 9107182 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 32
Study 9107182 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine-isosorbide dinitrate
Number of subjects: 32
Study 9107182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1526054 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocks of the infraorbital, infratrochlear and external nasal nerves by intranasal infiltration
Number of subjects: 50
Study 1526054 — intervention group
Group type: COMPARATOR
Intervention: Generalized infiltration of the nasal dorsum by an external route
Number of subjects: 50
Study 2861067 — intervention group
Group type: COMPARATOR
Intervention: 1 mg nebulized fenoterol (group A)
Number of subjects: 28
Study 2861067 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg fenoterol and 0.5 mg ipratropium (group B)
Number of subjects: 28
Study 31838440 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) program
Number of subjects: 43
Study 31838440 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 43
Study 30913162 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM) 0.3 g·kg⋅d for 1 week (loading phase) and 5 g·d for 7 weeks (maintenance phase)
Number of subjects: 19
Study 30913162 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM)
Number of subjects: 19
Study 30913162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 19
Study 26385030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 221
Study 26385030 — intervention group
Group type: COMPARATOR
Intervention: Intravenous loop diuretics
Number of subjects: 221
Study 23730862 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention for 12 weeks
Number of subjects: 58
Study 23730862 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 21957718 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training programs in physical education instruction
Number of subjects: 0
Study 21957718 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical education instruction
Number of subjects: 0
Study 19048243 — intervention group
Group type: COMPARATOR
Intervention: Exogenous alkaline phosphatase (AP) administered via 10-min IV infusions or 24-72 h continuous IV infusion (132.5-200 U kg(‐1) 24 h(‐1))
Number of subjects: 103
Study 19048243 — intervention group
Group type: COMPARATOR
Intervention: Exogenous alkaline phosphatase (AP) administered via 10-min IV infusions
Number of subjects: 103
Study 19048243 — intervention group
Group type: COMPARATOR
Intervention: Exogenous alkaline phosphatase (AP) administered via 24-72 h continuous IV infusion
Number of subjects: 103
Study 19048243 — intervention group
Group type: COMPARATOR
Intervention: Exogenous alkaline phosphatase (AP)
Number of subjects: 103
Study 16870769 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV plus LPV/RTV at 700 mg plus 400 mg/100 mg q12h simultaneously
Number of subjects: 11
Study 16870769 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV/RTV at 700 mg/100 mg q12h plus LPV/RTV at 400 mg/100 mg q12h, with doses separated by 4 h
Number of subjects: 11
Study 16870769 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV/RTV at 700 mg/100 mg q12h plus LPV/RTV at 400 mg/100 mg q12h, with doses separated by 12 h
Number of subjects: 11
Study 12779035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixtard 50 HM
Number of subjects: 26
Study 12779035 — intervention group
Group type: COMPARATOR
Intervention: Mixtard 30 HM
Number of subjects: 26
Study 12779035 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoPen 3
Number of subjects: 26
Study 12779035 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 26
Study 10948445 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0
Study 10948445 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 0
Study 9376337 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 30
Study 9376337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 30
Study 9376337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8462533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 0.39 mg kg‐1
Number of subjects: 60
Study 8462533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 0.5 mg kg‐1
Number of subjects: 60
Study 8462533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 0.63 mg kg‐1
Number of subjects: 60
Study 8462533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 0.79 mg kg‐1
Number of subjects: 60
Study 8462533 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1.0 mg kg‐1
Number of subjects: 60
Study 8462533 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 2579877 — intervention group
Group type: COMPARATOR
Intervention: 0.5% dl-S-596
Number of subjects: 31
Study 2579877 — intervention group
Group type: COMPARATOR
Intervention: 1% dl-carteolol
Number of subjects: 31
Study 2579877 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen (0.1%)
Number of subjects: 31
Study 31251795 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive chromosome screening (MICS) using blastocyst culture medium (BCM)
Number of subjects: 62
Study 31251795 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophectoderm (TE) biopsy
Number of subjects: 62
Study 31251795 — intervention group
Group type: EXPERIMENTAL
Intervention: MICS‐Inst
Number of subjects: 62
Study 30128853 — intervention group
Group type: EXPERIMENTAL
Intervention: L-menthol mouth rinse (0.01%)
Number of subjects: 10
Study 30128853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice ingestion (1.25 g kg-1)
Number of subjects: 10
Study 30128853 — intervention group
Group type: COMPARATOR
Intervention: Placebo-flavored non-calorific mouth rinse
Number of subjects: 10
Study 26410392 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered sugarcane molasses concentrate (FMC) administered as an oral supplement before a meal, with varying doses (exact doses not specified)
Number of subjects: 0
Study 26410392 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup (test meal 1)
Number of subjects: 0
Study 25001494 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging activations in unaffected siblings
Number of subjects: 15
Study 25001494 — intervention group
Group type: COMPARATOR
Intervention: Functional magnetic resonance imaging activations in healthy control subjects
Number of subjects: 15
Study 22665534 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide, vincristine, and dactinomycin (IVA)
Number of subjects: 457
Study 22665534 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-drug combination (IVA plus carboplatin, epirubicin, and etoposide)
Number of subjects: 457
Study 20502877 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 84
Study 20502877 — intervention group
Group type: COMPARATOR
Intervention: TVT-Secur
Number of subjects: 84
Study 17629089 — intervention group
Group type: EXPERIMENTAL
Intervention: lafutidine 10 mg
Number of subjects: 11
Study 17629089 — intervention group
Group type: COMPARATOR
Intervention: famotidine 20 mg
Number of subjects: 11
Study 16130870 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB)
Number of subjects: 25
Study 16130870 — intervention group
Group type: COMPARATOR
Intervention: Adper Prompt (PLP)
Number of subjects: 25
Study 16130870 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite (EXC)
Number of subjects: 25
Study 16130870 — intervention group
Group type: COMPARATOR
Intervention: AdheSE (ADH)
Number of subjects: 25
Study 16130870 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus (OPT)
Number of subjects: 25
Study 16130870 — intervention group
Group type: COMPARATOR
Intervention: OptiBond Solo Plus SE (OPTSE)
Number of subjects: 25
Study 16130870 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (PBNT)
Number of subjects: 25
Study 16130870 — intervention group
Group type: COMPARATOR
Intervention: Xeno III (XEN)
Number of subjects: 25
Study 16130870 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Step Plus (OST)
Number of subjects: 25
Study 16130870 — intervention group
Group type: COMPARATOR
Intervention: Tyrian SPE (TYR)
Number of subjects: 25
Study 12904140 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 12904140 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 0
Study 12904140 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study 9578178 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole
Number of subjects: 0
Study 9578178 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole alone
Number of subjects: 0
Study 9578178 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole after coronary artery bypass grafting
Number of subjects: 0
Study 9578178 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole in patients with occlusive peripheral vascular disease
Number of subjects: 0
Study 9578178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole in pharmacological stress testing
Number of subjects: 0
Study 9578178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole combined with warfarin
Number of subjects: 0
Study 8083636 — intervention group
Group type: EXPERIMENTAL
Intervention: PsH group (17%-30% pseudohomophones among nonwords)
Number of subjects: 0
Study 8083636 — intervention group
Group type: COMPARATOR
Intervention: NPsH group (no pseudohomophones)
Number of subjects: 0
Study 8083636 — intervention group
Group type: EXPERIMENTAL
Intervention: Double lexical decision paradigm
Number of subjects: 0
Study 2682348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary erucic acid therapy
Number of subjects: 12
Study 123815 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 456